Rheumatology

Investigators theorized that this questionnaire, in conjunction with autoantibody determination, could help screen for SLE in the early stages of the disease.

James Woody, MD, PhD, explains the key findings of the Phase 2b clinical trial, “Repurposing Anti-TNF for Treating Dupuytren's Disease (RIDD).”

Jessica Walsh, MD, explains the importance of understanding treatment satisfaction and decision-making in patients with axial spondyloarthritis based on patient-reported outcomes.

Roy Fleischmann, MD, explores the successful results of the novel IL-6 inhibitor, olokizumab, from 2 randomized clinical trials of the phase 3 global research program CREDO.

Crohn’s disease inflames the gastrointestinal tract and causes consistent abdominal pain and diarrhea. Upadacitinib (AbbVie), a reversible Janus kinase (JAK) inhibitor, may be able to help patients achieve clinical remission.

Selective Janus kinase (JAK) inhibitor, upadacitinib, is now intended for adults with moderate-to-severe rheumatoid arthritis (RA) who have had inadequate response or intolerance to at least 1 tumor necrosis factor (TNF) blocker.

Rheumatoid arthritis often requires long-term treatment with disease-modifying antirheumatic drugs (DMARDs), but tapering and even cessation of DMARDs can be considered for patients in remission. Test your knowledge of use of DMARDs in patients in remission with this quiz.

On this month's episode of Overdrive, Rheumatology Network interviewed Courtney Wells, PhD, MPH, MSW, to discuss the impact of COVID-19 on the quality of life of patients with rheumatic conditions, focusing on perceived risk and decision making.

Previous studies examining whether inflammatory disease was associated with an increased risk of Alzheimer's disease yielded mixed results.

Guselkumab is the first and only selective interleukin inhibitor therapy in the US that's approved for both moderate-severe plaque psoriasis and active psoriatic arthritis regardless of prior TNFi exposure.

Andrew Concoff, MD, explores the benefits of a gel that significantly improves clinical outcomes for patients with rheumatoid arthritis and decreases the need for concomitant medications.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending December 3, 2021.

“Managing pain is an important treatment goal in patients with ankylosing spondylitis, however, pain is often underestimated by clinical disease activity scoring tools, and 20% to 30% of patients report pain despite treatment with TNFis,” investigators stated.

Stuart Kassan, MD, discusses Rheumatology Research Foundation's recent patient webinar, "Just Diagnosed: Now What?”

Philip Mease, MD, explains the recent Phase 3 data from the DISCOVER-1 and DISCOVER-2 clinical trials which demonstrated guselkumab inhibited radiographic progression, and improved symptoms and pain in patients with active psoriatic arthritis (PsA).

Louis Bessette, MD, MSc, explains the impact of early pain improvement on patient-reported outcomes in patients with psoriatic arthritis.

Benjamin Terrier, MD, PhD, discusses his study and ACR presentation, “Rituximab versus Conventional Therapeutic Strategy for Remission Induction in Eosinophilic Granulomatosis with Polyangiitis: A Double-blind, Randomized, Controlled Trial.”

Paul R. Fortin, MD, MPH, FRCPC, discusses the impact of the COVID-19 vaccine in immunosuppressed adults and those with autoimmune diseases.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending November 26, 2021.

Ana-Maria Orbai, MD, FACR, MHS, explains how guselkumab improved PROMIS-29 scores in patients with psoriatic arthritis.

Soumya Chakravarty, MD, PhD, discusses the unmet patient needs in immune-mediated diseases and Janssen’s role in scientific innovation that allows patients to live their lives unburdened by disease.

Mithu Maheswaranathan, MD, discusses the association of health literacy in terms of both clinical and self-reported outcomes for patients with systemic lupus erythematosus.

Despite the increasing trend of PRP in knee osteoarthritis, most clinical guidelines do not recommend it due to a lack of evidence on its efficacy.

Robert Terkeltaub, MD, explains the results from a phase 2, dose-finding study to determine the safety and efficacy of tigulixostat in patients with gout.

Janus kinase (JAK) inhibitors are the newest class of drugs used to treat rheumatoid arthritis. How much do you know about these drugs? Test your knowledge with this quiz.

Courtney Wells, PhD, MPH, MSW, discusses the impact of the pandemic on the quality of life of patients with rheumatic conditions, with an emphasis on perceived risk and decision making.

Robert F Spiera, MD, explains background mycophenolate treatment and its associated improved outcomes in patients with systemic sclerosis receiving lenabasum.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending November 19, 2021.

Kelly Gavigan, MPH, discusses the changes in patient-reported outcome scores during the COVID-19 pandemic.

Eric Morand, MD, discusses “Attainment of the Lupus Low Disease Activity State in Response to Anifrolumab in 2 Phase 3 Trials.”